# Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

> **NCT01582243** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT01582243
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582243, "Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01582243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*